

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 28, 2020

**MIMEDX GROUP, INC.**

(Exact name of registrant as specified in charter)

**Florida**  
(State or other jurisdiction  
of incorporation)

**001-35887**  
(Commission  
File Number)

**26-2792552**  
(IRS Employer  
Identification No.)

**1775 West Oak Commons Ct., NE, Marietta GA 30062**  
(Address of principal executive offices) (Zip Code)

**Registrant's telephone number, including area code: (770) 651-9100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	n/a	n/a

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure**

On July 28, 2020, MiMedx Group, Inc. (the "**Company**" or the "**Registrant**") issued a press release announcing the hiring of Rohit Kashyap, Ph.D., as Executive Vice President and Chief Commercial Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	<a href="#">Press release dated July 28, 2020.</a>
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

**SIGNATURES**

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MIMEDX GROUP, INC.**

Date: July 28, 2020

By: /s/ Peter M. Carlson

\_\_\_\_\_  
Peter M. Carlson  
Chief Financial Officer



**MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as  
Executive Vice President and Chief Commercial Officer**

*Strategic Leader with Proven Record of Delivering Growth and Business Transformation*

MARIETTA, Ga., July 28, 2020 -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Rohit Kashyap, Ph.D., as Executive Vice President and Chief Commercial Officer, effective August 3, 2020. Dr. Kashyap is an accomplished strategic leader with experience in building successful global businesses, and a consistent track record of delivering growth, transforming business portfolios and building high impact teams. He brings to MiMedx more than 20 years of medical device experience, with a proven history of performance in developing strategies for market creation and commercial models that deliver value to patients and healthcare systems.

Timothy R. Wright, MiMedx Chief Executive Officer, commented, “MiMedx is a pioneer in the development of amniotic tissue technology, and our products have broad applicability across a range of applications. Our Company is now at an inflection point, with the opportunity to define the MiMedx brand, raise market awareness of the growing prevalence of chronic wounds and diseases such as diabetes, and communicate the clinical and economic value of our product portfolio. I am confident that Rohit, with his breadth of industry experience, will propel our patient-centric strategy forward as we work to drive organizational growth, market expansion and pipeline maturation.”

Dr. Kashyap added, “I am honored and excited to join MiMedx and help lead the commercial efforts into the next stage of its evolution. I believe the Company is uniquely positioned for growth with differentiated products that change people’s lives and, importantly, reduce the overall economic cost of healthcare. I look forward to working with the commercial team and senior leaders to increase the awareness and adoption of our products across multiple markets.”

**About Rohit Kashyap, Ph.D.**

Rohit Kashyap, Ph.D. served as the President of Global Commercial at Acelyty L.P. Inc. (formerly known as Kinetic Concepts, Inc.) since April 2019. Prior to that, Dr. Kashyap was the President of Americas, since January 2017, and President of North America, since October 2014. In these roles he led the company’s growth objectives by expanding core market leadership, identifying and developing new high-growth markets, and enhancing the overall product portfolio through the integration of additional businesses. Prior thereto, Dr. Kashyap served as Senior Vice President of Strategy and Business Development at Acelyty, Inc. from 2012 to 2014, and as Senior Vice President of Corporate Development from 2007 to 2010, with responsibility for the development of global strategic planning initiatives that incorporated organic growth, licensing and strategic acquisitions. Since joining the company in 1998, Dr. Kashyap contributed in various roles within the R&D, Licensing and Acquisition, and Global Marketing groups, including as Commercial Leader for international and emerging markets.

Dr. Kashyap earned his bachelor’s degree in Instrumentation and Control from the L.D. College of Engineering in Ahmedabad, India, and his master’s degree and doctorate in Biomedical Engineering from Case Western Reserve University. He also completed his MBA from the Kellogg School of Management at Northwestern University.

**About MiMedx**

MiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than 1.9 million allografts to date. For additional information, please visit [www.mimedx.com](http://www.mimedx.com).

**Contact:**

Hilary Dixon  
Investor Relations & Corporate Communications  
770.651.9066  
[investorrelations@mimedx.com](mailto:investorrelations@mimedx.com)